Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.

abstract：:Clinical pharmacologists are all dedicated to improving the use of medications and decreasing medication errors and adverse drug reactions. However, quality improvement requires that some significant parameters of quality be categorized, measured, and tracked to provide benchmarks to which future data (performance) ca...

journal_title：Journal of clinical pharmacology

authors： Benjamin DM,Pendrak RF

更新日期：2003-07-01 00:00:00

abstract：:The objective of this study was to evaluate the effect of the antireflux barrier formed by Na alginate on pH-metry-defined acid reflux events in preterms. Four times/day, 1 mL/kg of Na alginate was administered as an intervention to the preterm infants whose gastroesophageal reflux disease was confirmed by 24-hour pH ...

journal_title：Journal of clinical pharmacology

authors： Atasay B,Erdeve O,Arsan S,Türmen T

更新日期：2010-11-01 00:00:00

abstract：:CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. Population pharmacokinetics analyses were performed ...

journal_title：Journal of clinical pharmacology

authors： Wang Q,Banerjee K,Vasilinin G,Marier JF,Gibbons JA

更新日期：2019-05-01 00:00:00

abstract：:Vildagliptin is a potent and selective dipeptidyl peptidase IV inhibitor in development for the treatment of type 2 diabetes that improves glycemic control by enhancing alpha- and beta-cell responsiveness to glucose. Two open-label, single-dose, randomized, crossover studies in healthy subjects (ages 18-45 years) inve...

journal_title：Journal of clinical pharmacology

authors： Sunkara G,Sabo R,Wang Y,He YL,Campestrini J,Rosenberg M,Howard D,Dole WP

更新日期：2007-09-01 00:00:00

abstract：:Reduced bioavailability (F) due to hepatic first-pass extraction of an oral dose (D) is a well-known pharmacokinetic phenomenon. An integrated solution for Michaelis-Menten kinetics of the first-pass effect is derived from the maximal metabolic rate (Vm), volume of distribution (Vd), first order absorption rate consta...

journal_title：Journal of clinical pharmacology

authors： Keller F,Kunzendorf U,Walz G,Haller H,Offermann G

更新日期：1989-03-01 00:00:00

abstract：:A physiologically based pharmacokinetic model (PBPK) was built for citalopram using Simcyp-based absorption, distribution, metabolism, and excretion simulator. Various physicochemical properties of citalopram were obtained from the published literature. The in vitro-in vivo extrapolation method was used to predict cle...

journal_title：Journal of clinical pharmacology

authors： Wu X,Zhang H,Miah MK,Caritis SN,Venkataramanan R

更新日期：2020-04-01 00:00:00

abstract：:Ten years' experience with a system of modifying the scoring of examinations in pharmacology based on feedback comments from students on individual questions are analyzed. Each examination (3 per year for 10 years), approximately 100 items in length, was subjected to rigorous editing by a faculty committee and an inde...

journal_title：Journal of clinical pharmacology

authors： Smith CM

更新日期：1997-05-01 00:00:00

abstract：:Antiretrovirals may influence methadone exposure in HIV-1-infected patients receiving methadone for opiate addiction. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor for treating HIV-1 infection. In this open-label trial (NCT00744770), 13 HIV-negative volunteers continued on their regular stable methad...

journal_title：Journal of clinical pharmacology

authors： Crauwels HM,van Heeswijk RP,Vandevoorde A,Buelens A,Stevens M,Hoetelmans RM

更新日期：2014-02-01 00:00:00

abstract：:Renal electrolyte excretion patterns were determined in nonedematous healthy volunteers following bumetanide and furosemide in two separate clinical studies. In study 1, intravenous bumetanide was administered to 24 subjects at four dose levels. In study 2, bumetanide (1 or 2 mg) or furosemide (40 or 80 mg) was admini...

journal_title：Journal of clinical pharmacology

authors： Hutcheon DE,Vincent ME,Sandhu RS

更新日期：1981-11-01 00:00:00

abstract：:Cannabinoids, including smoked marijuana and delta9-tetrahydrocannabinol (THC) (dronabinol, Marinol), have been used to treat human immunodeficiency virus-1 (HIV)-associated anorexia and weight loss. Concerns have been raised, however, that these compounds might have adverse effects on the immune system of subjects wi...

journal_title：Journal of clinical pharmacology

authors： Bredt BM,Higuera-Alhino D,Shade SB,Hebert SJ,McCune JM,Abrams DI

更新日期：2002-11-01 00:00:00

abstract：:Sleep disturbances and decrements of daytime performance have been attributed to HMG-CoA reductase inhibitors. As a rule, lipophilic compounds more readily cross the blood-brain barrier and are more likely to affect central nervous system function. The authors compared the effects of lovastatin (40 mg), a lipophilic c...

journal_title：Journal of clinical pharmacology

authors： Kostis JB,Rosen RC,Wilson AC

更新日期：1994-10-01 00:00:00

abstract：:Compared with aminoglycosides, chloramphenicol, sulfonamides, tetracyclines, and even penicillins, the cephalosporins represent a remarkably safe class of antibiotics. Among the cephalosporins, the extended spectrum, third generation agents developed generally produce few side effects and appear to be less allergenic ...

journal_title：Journal of clinical pharmacology

authors： Neu HC

更新日期：1990-05-01 00:00:00

abstract：:In a double-blind, randomized, crossover study in ten patients with asthma, the effects on specific airway resistance of esmolol, a new ultra-short-acting beta 1-selective adrenoceptor blocker, were compared with those of placebo. Specific airway resistance was measured during increasing doses of esmolol infusion, dur...

journal_title：Journal of clinical pharmacology

authors： Sheppard D,DiStefano S,Byrd RC,Eschenbacher WL,Bell V,Steck J,Laddu A

更新日期：1986-03-01 00:00:00

abstract：:In the pivotal TEMPO 3:4 trial, the arginine vasopressin V2-receptor antagonist tolvaptan reduced the rate of kidney growth in patients with autosomal dominant polycystic kidney disease. Tolvaptan was initiated as daily morning/afternoon doses of 45/15 mg, and uptitrated weekly to 60/30 mg and 90/30 mg according to pa...

journal_title：Journal of clinical pharmacology

authors： Shoaf SE,Chapman AB,Torres VE,Ouyang J,Czerwiec FS

更新日期：2017-07-01 00:00:00

abstract：:After space-flights of less than ten days, orthostatic hypotension upon reentry is characterized by plasma volume depletion that may lead to activation of the Bezold-Jarisch reflex which is also considered to be the mechanism of vasovagal (neurocardiogenic) syncope. For space-flight of longer duration, loss of cardiov...

journal_title：Journal of clinical pharmacology

authors： Piwinski SE,Jankovic J,McElligott MA

更新日期：1994-05-01 00:00:00

abstract：:As part of a clinical trial investigating the level of nicotine replacement with different doses of transdermal therapy for smoking cessation, urine excretion rates of nicotine and cotinine were measured in 70 subjects while they were actively smoking (baseline) and for 6 consecutive inpatient days while they were rec...

journal_title：Journal of clinical pharmacology

authors： Lawson GM,Hurt RD,Dale LC,Offord KP,Croghan IT,Schroeder DR,Jiang NS

更新日期：1998-06-01 00:00:00

abstract：:Epoxieicosatrienoic acids (EETs) play a protective role against damaging processes in the kidney. We have assessed the effect of polymorphisms in EETs-producing enzymes (CYP2C8 and CYP2J2) and other proteins involved in calcineurin inhibitors (CNIs) disposition (CYP3A4, CYP3A5, and ABCB1) on graft function and clinica...

journal_title：Journal of clinical pharmacology

authors： Gervasini G,Garcia M,Macias RM,Benitez J,Caravaca F,Cubero JJ

更新日期：2013-04-01 00:00:00

abstract：:Guidelines have been developed by the Bureau of Drugs, FDA, for antinflammatory drug development. They address the problem of efficacy and safety testing but leave the definition of qualified investigators and appropriate subjects unstated. The natural history of rheumatoid arthritis, the most-studied chronic inflamma...

journal_title：Journal of clinical pharmacology

authors： Ehrlich GE

更新日期：1977-11-01 00:00:00

abstract：:The authors examined the pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in 17 patients (4 children, 13 adults) with B-lineage lymphoid malignancies, including 12 patients with acute lymphoblastic leukemia (ALL) and 5 patients with non-Hodgkin's lymphoma (NHL). The immunoconjugat...

journal_title：Journal of clinical pharmacology

authors： Chen CL,Levine A,Rao A,O'Neill K,Messinger Y,Myers DE,Goldman F,Hurvitz C,Casper JT,Uckun FM

更新日期：1999-12-01 00:00:00

abstract：:Advances in microcomputer technology provide new ways of incorporating PBL procedures in clinical pharmacology courses. Developments in graphics-user interfaces and analog/digital systems that display physiologic information directly on the monitor enable the computer to serve as a learning resource as laboratory clas...

journal_title：Journal of clinical pharmacology

authors： Hutcheon DE,el-Gawly HW

更新日期：1991-03-01 00:00:00

abstract：:Consumption of typical quantities of grapefruit juice (GFJ) increases the oral bioavailability of several CYP3A4 substrates without affecting their elimination, consistent with selective inhibition of intestinal but not hepatic CYP3A4. However, increases in the AUCs of CYP3A4 substrates recently associated with the co...

journal_title：Journal of clinical pharmacology

authors： Veronese ML,Gillen LP,Burke JP,Dorval EP,Hauck WW,Pequignot E,Waldman SA,Greenberg HE

更新日期：2003-08-01 00:00:00

abstract：:The effects on the upper gastrointestinal tract of five different preparations of KCl were compared in 90 healthy subjects treated with glycopyrrolate. The KCl preparations studied were wax-matrix KCl, microencapsulated KCl, liquid KCl, experimental extended-release capsules, experimental extended-release tablets,and ...

journal_title：Journal of clinical pharmacology

authors： Alsop WR,Moore JG,Rollins DE,Tolman KG

更新日期：1984-05-01 00:00:00

abstract：:The aim of this study was to apply individualized, physiologically-based pharmacokinetic (iPBPK-R) modeling of 14 CO2 production rates measured by the erythromycin breath test (ERMBT) to characterize the effect of hemodialysis on the function of nonrenal clearance pathways in patients with end-stage renal disease (ESR...

journal_title：Journal of clinical pharmacology

authors： Franchetti Y,Nolin TD

更新日期：2021-01-18 00:00:00

abstract：:Pharmacokinetic values of cibenzoline, a new, investigational, antiarrhythmic drug, were determined in 13 patients with varying degree of renal impairment, creatinine clearance range between 5 and 53 mL/min. Cibenzoline plasma levels were measured after direct intravenous injection of one single 1 mg/kg dose. The appa...

journal_title：Journal of clinical pharmacology

authors： Canal M,Flouvat B,Aubert P,Guedon J,Prinseau J,Baglin A

更新日期：1985-04-01 00:00:00

abstract：:In most Wuchereria bancrofti and Brugia malayi infections, the microfilaria are found in the blood in greatest number between 10 p.m. and 2 a.m., indicating that chronotherapy may be beneficial in treating such infections. This study reports the influence of time of administration on the pharmacokinetics of diethylcar...

journal_title：Journal of clinical pharmacology

authors： Bolla S,Boinpally RR,Poondru S,Devaraj R,Jasti BR

更新日期：2002-03-01 00:00:00

abstract：:The antihypertensive effect and safety of hydrochlorothiazide administration as a single drug and together with medroxalol were determined in 20 patients with primary hypertension. Following two biweekly intervals on placebo and hydrochlorothiazide, medroxalol was started at 100 mg three times a day and titrated again...

journal_title：Journal of clinical pharmacology

authors： Vlachakis ND,Valasquez M,Alexander N,Maronde RF

更新日期：1983-10-01 00:00:00

abstract：:The purpose of this analysis was to develop a population pharmacokinetic model for CS-917, an oral hypoglycemic prodrug, and its 3 metabolites. The population pharmacokinetic model was used to predict exposure of the active moiety R-125338 and thus to identify potential CS-917 dosage reduction criteria. The dataset in...

journal_title：Journal of clinical pharmacology

authors： Kastrissios H,Walker JR,Carrothers TJ,Kshirsagar S,Khariton T,Habtemariam B,Mager DE,Rohatagi S

更新日期：2012-03-01 00:00:00

abstract：:This report briefly discusses some aspects of autonomic cardiovascular dysfunction as related to changes in orthostatic function in patients, bed rest subjects, and astronauts. This relationship is described in normal individuals to provide the basis for discussion of parameters that may be altered in patients, bed re...

journal_title：Journal of clinical pharmacology

authors： Lathers CM,Charles JB

更新日期：1993-11-01 00:00:00

abstract：:Antibody-drug conjugates (ADCs) represent an innovative therapeutic approach that provides novel treatment options and hope for patients with cancer. By coupling monoclonal antibodies (mAbs) to cytotoxic small-molecule payloads with a plasma-stable linker, ADCs offer the potential for increased drug specificity and fe...

journal_title：Journal of clinical pharmacology

authors： Vezina HE,Cotreau M,Han TH,Gupta M

更新日期：2017-10-01 00:00:00

abstract：:To assess the effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin, a third-party blind, placebo-controlled, randomized, two-way crossover study was performed in 12 healthy volunteers. Each participant received single 30-mg oral doses of racemic warfarin sodium (Coumadin; DuPont Pharma, Wilmingt...

journal_title：Journal of clinical pharmacology

authors： Zhi J,Melia AT,Guerciolini R,Koss-Twardy SG,Passe SM,Rakhit A,Sadowski JA

更新日期：1996-07-01 00:00:00